These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

193 related items for PubMed ID: 25486586

  • 1. Complementary and synergistic activities of anti-V3, CD4bs and CD4i antibodies derived from a single individual can cover a wide range of HIV-1 strains.
    Ramirez Valdez KP, Kuwata T, Maruta Y, Tanaka K, Alam M, Yoshimura K, Matsushita S.
    Virology; 2015 Jan 15; 475():187-203. PubMed ID: 25486586
    [Abstract] [Full Text] [Related]

  • 2. Unique binding modes for the broad neutralizing activity of single-chain variable fragments (scFv) targeting CD4-induced epitopes.
    Tanaka K, Kuwata T, Alam M, Kaplan G, Takahama S, Valdez KPR, Roitburd-Berman A, Gershoni JM, Matsushita S.
    Retrovirology; 2017 Sep 22; 14(1):44. PubMed ID: 28938888
    [Abstract] [Full Text] [Related]

  • 3. Anti-V3/Glycan and Anti-MPER Neutralizing Antibodies, but Not Anti-V2/Glycan Site Antibodies, Are Strongly Associated with Greater Anti-HIV-1 Neutralization Breadth and Potency.
    Jacob RA, Moyo T, Schomaker M, Abrahams F, Grau Pujol B, Dorfman JR.
    J Virol; 2015 May 22; 89(10):5264-75. PubMed ID: 25673728
    [Abstract] [Full Text] [Related]

  • 4. A broad range of mutations in HIV-1 neutralizing human monoclonal antibodies specific for V2, V3, and the CD4 binding site.
    Li L, Wang XH, Williams C, Volsky B, Steczko O, Seaman MS, Luthra K, Nyambi P, Nadas A, Giudicelli V, Lefranc MP, Zolla-Pazner S, Gorny MK.
    Mol Immunol; 2015 Aug 22; 66(2):364-74. PubMed ID: 25965315
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Evolution of cross-neutralizing antibodies and mapping epitope specificity in plasma of chronic HIV-1-infected antiretroviral therapy-naïve children from India.
    Makhdoomi MA, Khan L, Kumar S, Aggarwal H, Singh R, Lodha R, Singla M, Das BK, Kabra SK, Luthra K.
    J Gen Virol; 2017 Jul 22; 98(7):1879-1891. PubMed ID: 28696188
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Synergistic neutralization of human immunodeficiency virus type 1 by a chimpanzee monoclonal antibody against the V2 domain of gp120 in combination with monoclonal antibodies against the V3 loop and the CD4-binding site.
    Vijh-Warrier S, Pinter A, Honnen WJ, Tilley SA.
    J Virol; 1996 Jul 22; 70(7):4466-73. PubMed ID: 8676471
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Production and characterization of human anti-V3 monoclonal antibodies from the cells of HIV-1 infected Indian donors.
    Andrabi R, Kumar R, Bala M, Nair A, Biswas A, Wig N, Kumar P, Pal R, Sinha S, Luthra K.
    Virol J; 2012 Sep 12; 9():196. PubMed ID: 22971578
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Two major groups of neutralizing anti-gp120 antibodies exist in HIV-infected individuals. Evidence for epitope diversity around the CD4 attachment site.
    Chamat S, Nara P, Berquist L, Whalley A, Morrow WJ, Köhler H, Kang CY.
    J Immunol; 1992 Jul 15; 149(2):649-54. PubMed ID: 1378074
    [Abstract] [Full Text] [Related]

  • 18. Improving neutralization potency and breadth by combining broadly reactive HIV-1 antibodies targeting major neutralization epitopes.
    Kong R, Louder MK, Wagh K, Bailer RT, deCamp A, Greene K, Gao H, Taft JD, Gazumyan A, Liu C, Nussenzweig MC, Korber B, Montefiori DC, Mascola JR.
    J Virol; 2015 Mar 15; 89(5):2659-71. PubMed ID: 25520506
    [Abstract] [Full Text] [Related]

  • 19. Evaluation of monoclonal antibodies to HIV-1 envelope by neutralization and binding assays: an international collaboration.
    D'Souza MP, Geyer SJ, Hanson CV, Hendry RM, Milman G.
    AIDS; 1994 Feb 15; 8(2):169-81. PubMed ID: 7519019
    [Abstract] [Full Text] [Related]

  • 20. HIV-1 neutralizing antibodies display dual recognition of the primary and coreceptor binding sites and preferential binding to fully cleaved envelope glycoproteins.
    Li Y, O'Dell S, Wilson R, Wu X, Schmidt SD, Hogerkorp CM, Louder MK, Longo NS, Poulsen C, Guenaga J, Chakrabarti BK, Doria-Rose N, Roederer M, Connors M, Mascola JR, Wyatt RT.
    J Virol; 2012 Oct 15; 86(20):11231-41. PubMed ID: 22875963
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.